Dr Andreas Bender is since 2025 Professor for Machine Learning in Medicine at the Department of Medicine at Khalifa University, Abu Dhabi, analyzing heterogenous chemical, biological and medical data. Before this post, he has been Professor for Molecular Informatics at Cambridge University and a Director for Digital Life Sciences at Nuvisan/Berlin, as well as Associate Director for Data Science and AI in the Clinical Pharmacology & Safety Sciences group at AstraZeneca/Cambridge, UK. In his work, Andreas is involved with the integration and analysis of chemical and biological data from different sources, such as structural and bioactivity data, gene expression readouts, cellular imaging data, pathway information, electronic health records, etc., for clinically relevant decision making.

On the entrepreneurial side, Andreas was involved in setting up Healx Ltd., for data-driven drug repurposing, and PharmEnable Ltd., for designing novel chemistry for targets that are difficult to drug conventially, both based in Cambridge/UK. More recently, he was involved in establishing Pangea Bio, a clinical stage company located in London/UK as well as Berlin/Germany, working on CNS drug discovery supported by historical use information. He received his PhD from the University of Cambridge and worked in the Lead Discovery Informatics group at Novartis in Cambridge/MA as well as at Leiden University in the Netherlands before his current post